Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Boehringer Ingelheim International Gmbh patents (2016 archive)


Recent patent applications related to Boehringer Ingelheim International Gmbh. Boehringer Ingelheim International Gmbh is listed as an Agent/Assignee. Note: Boehringer Ingelheim International Gmbh may have other listings under different names/spellings. We're not affiliated with Boehringer Ingelheim International Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Boehringer Ingelheim International Gmbh-related inventors


Olefin substituted oxindoles having ampk activity

The present invention relates to compounds of formula (i), which have valuable pharmacological properties, in particular are activators of ampk and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.. ... Boehringer Ingelheim International Gmbh

Cx3cr1-binding polypeptides

. . The present invention relates to cx3cr1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.. ... Boehringer Ingelheim International Gmbh

Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin

The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.. . ... Boehringer Ingelheim International Gmbh

Artificial introns

The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences.. ... Boehringer Ingelheim International Gmbh

Glucagon analogues

The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. ... Boehringer Ingelheim International Gmbh

Pyrazole compounds as btk inhibitors

. . The present invention encompasses compounds of the formula (i) wherein the groups r1, cy, and y are defined herein, which are suitable for the treatment of diseases related to btk, process of making, pharmaceutical preparations which contain compounds and their methods of use.. . ... Boehringer Ingelheim International Gmbh

Anti-il-23 antibodies

The present invention relates to anti-il-23p19 binding compounds, in particular new humanized anti-il-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.. . ... Boehringer Ingelheim International Gmbh

Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

The present invention relates to a suspension formulation containing the active substance 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl -methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.. . ... Boehringer Ingelheim International Gmbh

Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a dpp-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.. . ... Boehringer Ingelheim International Gmbh

Methods of treating diseases

This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-il-23a antibodies.. . ... Boehringer Ingelheim International Gmbh

Method for treatment of solid malignancies including advanced or metastatic solid malignancies

The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof for treating patients suffering from solid malignancies including advanced or metastatic solid malignancies comprising a high frequency administration of volasertib according to a specific dosage schedule.. . ... Boehringer Ingelheim International Gmbh

Methods of administering an egfr inhibitor

. . Disclosed are methods of treating a patient having cancer with an egfr inhibitor requiring an active step of avoiding or modifying the co-administration of such drugs with p-gp modulators. This invention also relates to a medicament for treating a patient having cancer, comprising an egfr inhibitor as the active product ingredient, customized for avoiding co-administration with p-gp inducers and/or inhibitors by an instruction added to the medicament or the package containing said medicament.. ... Boehringer Ingelheim International Gmbh

Amylin analogues

. . The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.. ... Boehringer Ingelheim International Gmbh

Stable powder formulation containing an anticholingeric agent

A spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which x− is a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, and iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, with the exception of amino carboxylic acids, to preferably fumaric acid, oxalic acid, or diacetic acid, and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, α-hydroxycaprylic acid or gluconic acid.. . ... Boehringer Ingelheim International Gmbh

09/01/16 / #20160250218

Pharmaceutical combination

The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.. ... Boehringer Ingelheim International Gmbh

08/25/16 / #20160244446

Heteroaryl syk inhibitors

. . The invention relates to new substituted heteroaryls of formula (1), wherein a is selected from the group consisting of n and ch, d is ch, e is selected from the group consisting of c and n, t is c, g is selected from the group consisting of c and n, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein r1, m and r3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. . ... Boehringer Ingelheim International Gmbh

08/25/16 / #20160243124

Method for treating acute myeloid leukemia

The present invention relates to the use of bi 6727 or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) comprising the administration of a high dose of bi 6727 according to a specific dosage schedule, optionally in combination with cytarabine.. . ... Boehringer Ingelheim International Gmbh

08/18/16 / #20160235680

Pharmaceutical compositions

. . The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a dpp-4 inhibitor drug and/or a sglt-2 inhibitor drug, and metformin xr, processes for the preparation thereof, and their use to treat certain diseases.. . ... Boehringer Ingelheim International Gmbh

08/04/16 / #20160222124

Anti-cd40 antibodies

The present invention relates to new humanized antagonistic anti-cd40 antibodies and therapeutic and diagnostic methods and compositions for using the same.. . ... Boehringer Ingelheim International Gmbh

08/04/16 / #20160222102

Methods of treating inflammatory diseases

This invention generally relates to methods for the treatment of il-23 related diseases, in particular inflammatory diseases, such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-spa), including ankylosing spondylitis and non-radiographic ax-spa, utilizing anti-il-23a antibodies.. . ... Boehringer Ingelheim International Gmbh

07/21/16 / #20160206678

Hcv combination therapy

Aspects of this invention include methods comprising administering a combination of a compound (1) below, including particular crystalline forms thereof and pharmaceutically acceptable salts thereof, with at least one further selected hcv inhibiting compound as described herein for the treatment of hepatitis c viral (hcv) infection. The methods can be conducted by administering the compound (1) and the at least one further selected hcv inhibiting compound separately or together, including as a regimen of treatment.. ... Boehringer Ingelheim International Gmbh

07/21/16 / #20160206620

Purin derivatives for use in the treatment of fab-related diseases

The present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for wound healing preferably in diabetic patients.. . ... Boehringer Ingelheim International Gmbh

07/14/16 / #20160200806

Vegf-binding molecules

. . Vegf-binding molecules, preferably vegf-binding immunoglobulin single variable domains like vhhs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with vegf-mediated effects on angiogenesis. Nucleic acids encoding vegf-binding molecules, host cells and methods for preparing same.. ... Boehringer Ingelheim International Gmbh

07/14/16 / #20160199488

Combination therapy for neoplasia treatment

The present invention relates to an insulin-like growth factor (igf) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (bph), prostate cancer, and particularly crpc, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.. ... Boehringer Ingelheim International Gmbh

07/07/16 / #20160193433

Inhaler

. . An inhaler for delivering a preferably powdered formulation from a blister strip having a plurality of blister pouches. In order to achieve a compact simple construction for the inhaler and an easy action for the blister strip, the carrier extends over a circumferential angle of the inhaler of less than 360°. ... Boehringer Ingelheim International Gmbh

07/07/16 / #20160193267

Lozenge for treating sore throat, hoarseness and associated dry cough, and inflammatory diseases of the oral and pharyngeal cavity

The present invention relates to a pharmaceutical formulation containing a combination of (a) at least one astringent active substance and (b) at least one mucilaginous drug and the use thereof for the prevention or treatment of inflammatory diseases of the oropharyngeal region and for the treatment of painful irritations of the mucosa in the oropharyngeal region and associated irritable cough.. . ... Boehringer Ingelheim International Gmbh

06/09/16 / #20160158264

Pharmaceutical composition, methods for treating and uses thereof

. . The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a sglt-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.. ... Boehringer Ingelheim International Gmbh

05/26/16 / #20160144138

Filter system for use in medical devices

The invention relates to a medical hand-held device, in particular an atomizer (1), for dispensing a liquid pharmaceutical preparation from a container with a discharge nozzle for the pharmaceutical preparation and located upstream from the discharge nozzle there is a multiple-stage filter system.. . ... Boehringer Ingelheim International Gmbh

05/26/16 / #20160143906

Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment

The present invention relates to a beneficial treatment of tumours in patients suffering from nsclc, and to a clinical marker useful as predictive variable of the responsiveness of tumours in patients suffering from nsclc. The present invention further relates to a method for selecting patients likely to respond to a given therapy, wherein said method optionally comprises the use of a specific clinical marker. ... Boehringer Ingelheim International Gmbh

05/19/16 / #20160137729

Anti cd37 antibodies

. . Chimeric and humanized anti-cd37 antibodies and pharmaceutical compositions containing them are useful for the treatment of b cell malignancies and autoimmune and inflammatory diseases that involve b cells in their pathology.. . ... Boehringer Ingelheim International Gmbh

05/19/16 / #20160136180

Purin derivatives for use in the treatment of fab-related diseases

The invention is directed to the use of selected purine derivatives for the treatment of hyperproliferative diseases.. . ... Boehringer Ingelheim International Gmbh

05/12/16 / #20160131655

Bcma-based stratification and therapy for multiple myeloma patients

. . . . The present invention relates to methods for the stratification of a multiple myeloma (mm) patient comprising determining whether or not b-cells, preferably malignant b-cells of said patient express bcma protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (mm) therapy is based on whether or not bcma is expressed on the cell surface of b-cells, preferably malignant b-cells of a patient. ... Boehringer Ingelheim International Gmbh

05/12/16 / #20160130226

Spiro-substituted oxindole derivatives having ampk activity

The present invention relates to compounds of formula (i), which have valuable pharmacological properties, in particular are activators of ampk and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.. ... Boehringer Ingelheim International Gmbh

05/05/16 / #20160122352

Polymorphs

The invention relates to polymorphous crystal modifications of a dpp-iv inhibitor, the preparation thereof and the use thereof for preparing a medicament.. . ... Boehringer Ingelheim International Gmbh

04/07/16 / #20160095992

Adapter, inhalation device, and atomizer

An inhalation device includes: a chamber for intermediate storage of an aerosol, a first connection for a nebuliser that produces the aerosol, a second connection on a patient side for delivering the aerosol, and a third connection for breathable air, where the chamber is fluidically connected in a valve-free manner on an inlet side to the first connection when the nebuliser is attached, and the chamber is connected to the third connection in parallel on the inlet side via an inlet valve so that the breathable air from the third connection flows into the chamber.. . ... Boehringer Ingelheim International Gmbh

04/07/16 / #20160095863

Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with quizartinib or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).. . ... Boehringer Ingelheim International Gmbh

03/31/16 / #20160089373

Cardio- and renoprotective antidiabetic therapy

The present invention relates to a certain dpp-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.. . ... Boehringer Ingelheim International Gmbh

03/24/16 / #20160082011

Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome

. . . . The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain dpp-4 inhibitor, as well as to the use of a certain dpp-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.. . ... Boehringer Ingelheim International Gmbh

03/17/16 / #20160074415

Methods of treatment and pharmaceutical compositions using an sglt-2 inhibitor and a neuroleptic agent

. . . . . . . . The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an sglt2 inhibitor.. . ... Boehringer Ingelheim International Gmbh

03/03/16 / #20160058769

Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

. . . . The present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.. . ... Boehringer Ingelheim International Gmbh

02/18/16 / #20160045436

Pharmaceutical formulation

. . The present invention relates to pharmaceutical formulations of highly active drugs with limited shelf-life in aqueous media, suitable to be administered by a caregiver person to a patient avoiding or minimizing the risk of exposure, contact or contamination of the caregiver person with the active product ingredient (api), preferably an egfr-tki such as afatinib dimaleate.. . ... Boehringer Ingelheim International Gmbh

02/11/16 / #20160038525

Pharmaceutical composition, methods for treating and uses thereof

. . . . . . . . The present invention relates to certain sglt-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.. . ... Boehringer Ingelheim International Gmbh

02/11/16 / #20160038524

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain sglt-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (ckd).. . ... Boehringer Ingelheim International Gmbh

02/11/16 / #20160038523

Pharmaceutical composition, methods for treating and uses thereof

The present invention relates to certain sglt-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such sglt-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain sglt-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.. ... Boehringer Ingelheim International Gmbh

02/11/16 / #20160038501

Pharmaceutical compositions comprising bi-1356 and metformin

The present invention relates to therapeutic uses of pharmaceutical compositions or combinations of a dpp-4 inhibitor with metformin.. . ... Boehringer Ingelheim International Gmbh

02/11/16 / #20160038500

Combination therapy

The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a glp-1 receptor agonist and a dpp-4 inhibitor.. . ... Boehringer Ingelheim International Gmbh

02/04/16 / #20160030385

Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

. . . . . . . . The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, visceral obesity and abdominal obesity, and metabolic syndrome.. . ... Boehringer Ingelheim International Gmbh

02/04/16 / #20160030336

Oral disintegrating tablet

A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.. . ... Boehringer Ingelheim International Gmbh

01/28/16 / #20160022687

Dpp iv inhibitor formulations

. . The present invention relates to pharmaceutical compositions of dpp iv inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.. . ... Boehringer Ingelheim International Gmbh

01/28/16 / #20160022672

Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

The present invention relates to a suspension formulation containing the active substance 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said to capsule comprising said suspension formulation and to the packaging material for the finished capsule.. . ... Boehringer Ingelheim International Gmbh

01/21/16 / #20160016990

Protein purification by means of aqueous two-phase centrifugal extraction

The invention relates to a method for the selective purification and concentration of immunoglobulins or other proteins by means of an aqueous two-phase system using a centrifugal extractor.. . ... Boehringer Ingelheim International Gmbh

01/21/16 / #20160015714

Use of a dpp-4 inhibitor in autoimmune diabetes, particularly lada

The present invention relates to methods for treating and/or preventing autoimmune diabetes, particularly lada, as well as diseases related or associated therewith, comprising the administration of an effective amount of a certain dpp-4 inhibitor, as well as to the use of a certain dpp-4 inhibitor for modifying disease trajectory of autoimmune diabetes (particularly lada).. . ... Boehringer Ingelheim International Gmbh

01/07/16 / #20160000816

Pharmaceutical composition, methods for treating and uses thereof

. . The present invention relates to certain sglt-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such sglt-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain sglt-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.. ... Boehringer Ingelheim International Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Boehringer Ingelheim International Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Boehringer Ingelheim International Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###